Skip to main content
SpringerLink
Log in

Chemosensitivity and cytokine sensitivity of malignant mesothelioma

  • Original Articles
  • Chemosensitivity, Cytokines, Mesothelioma
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Malignant mesothelioma arises in serosal tissues, is locally invasive, and is usually resistant to chemotherapeutic agents used clinically. To determine whether resistance to cytotoxic drugs was an inherent characteristic of mesothelioma cells, we performed in vitro chemosensitivity testing on five fully characterised human malignant mesothelioma cell lines and, for comparison, on three lines representative of clinically drug-resistant solidtissue carcinomas using the MTT (tetrazolium bromide) assay system. Mesothelioma cell lines were intrinsically resistant to eight common antineoplastic drugs, with concentrations that produced a 50% reduction in optical density (IC50 values) for all drugs being equivalent, if not higher, for mesothelioma cell lines as compared with lung and colon carcinoma cell lines. We then investigated the direct anti-mesothelioma activity of recombinant human cytokines with their antineoplastic properties. All five mesothelioma cell lines were resistant to tumour necrosis factor, but they displayed varying degrees of sensitivity to interferons (IFNs). IFNγ directly inhibited the growth of two of five mesothelioma lines. IFNα displayed little activity against four of five mesothelioma lines. The mesothelioma cells that were sensitive to IFNα were resistant to IFNγ, indicating that sensitivity to IFNs is not a genetic characteristic of malignant mesothelioma cells. Significant interactions between cytokines in combination were not observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aisner J, Wiernik PH (1981) Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 8 (3): 335–343

    Google Scholar 

  2. Albert AS, Falkson G, Goedhals L, Vorobiof DA, Van Der Merwe CA (1988) Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 6 (3): 527–535

    Google Scholar 

  3. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DJ, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589–601

    Google Scholar 

  4. Armstrong BK, Musk AW, Baker JE, Hunt JM, Newall CC, Henzell HR, Blunsdon BS, Clarke-Hundley MD, Woodward SD (1984) Epidemiology of malignant mesothelioma in Western Australia. Med J Aust 141: 86–88

    Google Scholar 

  5. Armstrong BK, De Klerk NH, Musk AW, Hobbs MST (1988) Mortality in miners and millers of crocidolite in Western Australia. Br J Ind Med 45: 5–13

    Google Scholar 

  6. Ball ED, Sorenson GD, Pettengill OS (1986) Expression of myeloid and major histocompatibility antigens on small cell carcinoma of the lung cell lines analysed by cytofluorography: modulation by γ-interferon. Cancer Res 46: 2335–2339

    Google Scholar 

  7. Bowman RV, Whitaker D, Manning LS, Davis MR, Robinson BWS (1991) Interaction between actinomycin D and tumor necrosis factor in a nude mouse model of human malignant mesothelioma —cachexia without oncolysis. Cancer 67: 2495–2500

    Google Scholar 

  8. Bradley G, Juranka PF, Ling V (1988). Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87–128

    Google Scholar 

  9. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay assessment of chemosensitivity testing. Cancer Res 47: 936–942

    Google Scholar 

  10. Christmas TI, Musk AW, Robinson BWS (1990) Phase II study of recombinant human alpha interferon therapy in malignant mesothelioma (abstract 1678). Proc Am Assoc Cancer Res 31: 283

    Google Scholar 

  11. Christmas TI, Manning LS, Davis MR, Robinson BWS, Garlepp MJ (1991) HLA antigen expression and malignant mesothelioma. Am J Respir Cell Mol Biol (in press)

  12. Craighead JE, Mossman BT (1982) The pathogenesis of asbestos-associated disease. N Engl J Med 306: 1446–1455

    Google Scholar 

  13. Da Valle MJ, Faber LP, Kittle CF, Jensik RJ (1986) Extrapleural pneumonectomy for diffuse malignant mesothelioma. Ann Thorac Surg 42: 612–618

    Google Scholar 

  14. Foon KA, Maluish AE, Abrams PG, Wrightington S, Stevenson HC, Alarif A, Fer MF, Overton WR, Pode M, Schnipper EF, Jaffe ES, Herberman RB (1986) Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia: therapeutic and immunologic results. Am J Med 80: 351–356

    Google Scholar 

  15. Goldstein LJ, Galski H, Fojo A, Willingham M, Shinn-Liang L, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Guttesman MM, Pasten I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116–124

    Google Scholar 

  16. Lerner HJ, Schoenfeld DA, Martin A, Falkson G, Borden E (1983) Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52: 1981–1985

    Google Scholar 

  17. Manning LS, Bowman RV, Darby SB, Robinson BWS (1989) Susceptibility of fresh and cultured human malignant mesothelioma cells to lysis by natural killer (NK) and lymphokine-activated killer (LAK) cells. Am Rev Respir Dis 139: 1369–1374

    Google Scholar 

  18. Manning LS, Bowman RV, Davis MR, Robinson BWS (1989) Indomethacin augments lymphokine-activated killer (LAK) cell generation by patients with malignant mesothelioma. Clin Immunol Immunopathol 53: 68–77

    Google Scholar 

  19. Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, Musk AW, Robinson BWS (1991) Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 47: 285–290

    Google Scholar 

  20. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63

    Google Scholar 

  21. Musk AW, Woodward SD (1982) Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia. Aust NZ J Med 12: 229–232

    Google Scholar 

  22. Musk AW, Bowman RV, Christmas TI, Robinson BWS (1991) Management of malignant mesothelioma. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D (eds) Malignant mesothelioma, Hemisphere, New York (in press)

    Google Scholar 

  23. Page M, Bejaoui N, Clinq-Mars B, Lemieux P (1988) Optimization of the tetrazolium-based colorimetric assay for the measurement of cell number and cytotoxicity. Int J Immunopharmacol 10 (7): 785–793

    Google Scholar 

  24. Park JG, Kramer BS, Steinberg SM, Carmichael J, Collins JM, Minna JD, Gazdar AF (1987) Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res 47: 5875–5879

    Google Scholar 

  25. Salmon SE, Young L, Scuderi P, Clark B (1987) Antineoplastic effects of tumor necrosis factor alone and in combination with γ-interferon on tumor biopsies in clonogenic assay. J Clin Oncol 5: 1816–1821

    Google Scholar 

  26. Schiller JH, Bittner G, Storer B, Willson JKV (1987) Synergistic antitumor effects of tumor necrosis factor and γ-interferon on human colon carcinoma cell lines. Cancer Res 47: 2809–2813

    Google Scholar 

  27. Schmiegel WH, Caesar J, Kalthoff H, Greten H, Schreiber HW, Thile HG (1988) Antiproliferative effects exerted by recombinant human tumor necrosis factor α (TNF-α) and interferon-γ (IFNγ) on human pancreatic cell lines. Pancreas 3: 180–188

    Google Scholar 

  28. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS (1990) P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 21 (1): 34–38

    Google Scholar 

  29. Weisenthal LM, Yong-Zhuang Su, Duarte TE, Nagourney RA (1988) Non-clonogenic in vitro assays for predicting sensitivity to cancer chemotherapy. In: Hall TC (ed) Progress in clinical and biological research — prediction of response to cancer therapy, vol 276. Alan R Liss, New York pp 75–92

    Google Scholar 

  30. Whitaker D, Manning LS, Robinson BWS, Shilkin KB (1991) The pathobiology of the mesothelium. In: Henderson KW, Shilkin KB, Langlois SLP, Whitaker D (ed) Malignant mesothelioma. Hemisphere, New York (in press)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Western Australia, 6009, Nedlands, Western, Australia

    R. V. Bowman, L. S. Manning, M. R. Davis & B. W. S. Robinson

  2. Department of Respiratory Medicine, QEII Medical Centre, 4th Floor G Block, 6009, Nedlands, Western Australia

    R. V. Bowman, L. S. Manning, M. R. Davis & B. W. S. Robinson

Authors
  1. R. V. Bowman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. S. Manning
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. R. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. W. S. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bowman, R.V., Manning, L.S., Davis, M.R. et al. Chemosensitivity and cytokine sensitivity of malignant mesothelioma. Cancer Chemother. Pharmacol. 28, 420–426 (1991). https://doi.org/10.1007/BF00685817

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685817

Keywords

Search

Navigation